Sun Pharmaceutical Industries Limited

NSEI:SUNPHARMA Stock Report

Market Cap: ₹4.4t

Sun Pharmaceutical Industries Past Earnings Performance

Past criteria checks 5/6

Sun Pharmaceutical Industries has been growing earnings at an average annual rate of 28.5%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 10.4% per year. Sun Pharmaceutical Industries's return on equity is 16%, and it has net margins of 22%.

Key information

28.5%

Earnings growth rate

28.6%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate10.4%
Return on equity16.0%
Net Margin22.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?

Nov 18
Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?

Sun Pharmaceutical Industries Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Oct 31
Sun Pharmaceutical Industries Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

We Ran A Stock Scan For Earnings Growth And Sun Pharmaceutical Industries (NSE:SUNPHARMA) Passed With Ease

Oct 21
We Ran A Stock Scan For Earnings Growth And Sun Pharmaceutical Industries (NSE:SUNPHARMA) Passed With Ease

Pinning Down Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Difficult Right Now

Aug 24
Pinning Down Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Difficult Right Now

Sun Pharmaceutical Industries Limited Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next

Aug 06
Sun Pharmaceutical Industries Limited Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next

This Is The Reason Why We Think Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Might Be Underpaid

Jul 30
This Is The Reason Why We Think Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Might Be Underpaid

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Ticks All The Boxes When It Comes To Earnings Growth

Jun 30
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Ticks All The Boxes When It Comes To Earnings Growth

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet

Jun 12
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet

Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

May 25
Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Price Is Out Of Tune With Earnings

May 22
Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Price Is Out Of Tune With Earnings

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet

Mar 13
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet

Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's

Feb 03
Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's

Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today

Jan 05
Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today

Revenue & Expenses Breakdown

How Sun Pharmaceutical Industries makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NSEI:SUNPHARMA Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24503,077110,54196,6840
30 Jun 24492,088103,89595,5510
31 Mar 24484,96995,76495,0250
31 Dec 23474,44689,06393,6810
30 Sep 23463,04985,48590,4190
30 Jun 23450,64884,35286,8210
31 Mar 23438,85784,73683,5490
31 Dec 22424,01842,11980,5490
30 Sep 22410,23941,04778,6880
30 Jun 22396,97538,89476,1690
31 Mar 22386,54532,72773,5440
31 Dec 21377,30764,44171,3540
30 Sep 21367,04462,37870,0490
30 Jun 21356,31660,03668,6190
31 Mar 21334,98129,03869,0420
31 Dec 20331,60124,09568,7290
30 Sep 20324,78214,70667,0160
30 Jun 20320,4847,21965,8100
31 Mar 20328,37537,64963,9860
31 Dec 19318,16540,01064,1490
30 Sep 19314,01843,29363,6080
30 Jun 19302,16129,95662,1010
31 Mar 19290,65926,65461,0270
31 Dec 18288,05234,37958,5390
30 Sep 18277,18224,38057,3160
30 Jun 18275,04835,69054,7020
31 Mar 18264,15520,95754,8140
31 Dec 17263,81120,76354,0070
30 Sep 17276,53031,82752,4320
30 Jun 17295,31045,05749,9290
31 Mar 17313,08169,64450,2850
31 Dec 16319,18573,27049,9860
30 Sep 16311,43174,00049,2120
30 Jun 16297,51261,93748,0120
31 Mar 16281,08645,45749,0760
31 Dec 15266,28138,91595,3690
30 Sep 15264,67028,70295,0000
30 Jun 15276,42238,15045,6080
31 Mar 15273,92045,39446,4830
31 Dec 14170,76559,14145,5860
30 Sep 14170,83560,20245,0360
30 Jun 14165,25058,10044,6800
31 Mar 14160,80431,41544,0400
31 Dec 13150,93326,10435,0710

Quality Earnings: SUNPHARMA has high quality earnings.

Growing Profit Margin: SUNPHARMA's current net profit margins (22%) are higher than last year (18.5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SUNPHARMA's earnings have grown significantly by 28.5% per year over the past 5 years.

Accelerating Growth: SUNPHARMA's earnings growth over the past year (29.3%) exceeds its 5-year average (28.5% per year).

Earnings vs Industry: SUNPHARMA earnings growth over the past year (29.3%) exceeded the Pharmaceuticals industry 20.4%.


Return on Equity

High ROE: SUNPHARMA's Return on Equity (16%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 19:54
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sun Pharmaceutical Industries Limited is covered by 73 analysts. 36 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nitin BhasinAmbit Capital
Prashant NairAmbit Capital
null nullAnand Rathi Shares and Stock Brokers Limited